1/24/2023 – Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect

12/15/2022 – Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

12/13/2022 – Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)

12/1/2022 – Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

11/23/2022 – Awakn Life Sciences Announces Location for Larger Oslo Clinic

11/9/2022 – Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York